# Study of of URC102 to Assess the Efficacy and Safety in Gout Patients

> **NCT04804111** · PHASE2 · COMPLETED · sponsor: **JW Pharmaceutical** · enrollment: 171 (actual)

## Conditions studied

- Gout

## Interventions

- **DRUG:** arm 0
- **DRUG:** arm 1
- **DRUG:** arm 2
- **DRUG:** arm 3
- **DRUG:** arm 4

## Key facts

- **NCT ID:** NCT04804111
- **Lead sponsor:** JW Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-21
- **Primary completion:** 2020-09-04
- **Final completion:** 2020-11-29
- **Target enrollment:** 171 (ACTUAL)
- **Last updated:** 2021-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04804111

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04804111, "Study of of URC102 to Assess the Efficacy and Safety in Gout Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04804111. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*